Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

FEMY

Femasys Inc

Apr 10 • 04:00PM ET

0.3970

+0.0018 0.46 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: IOVA AXSM KALA MANH TMDX VRCA HSDT LBRT HOOK VIVS

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.56	Insider Own	9.82%	Shs Outstand	59.60M	Perf Week	-9.61%
Market Cap	23.98M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	0.00%	Shs Float	54.46M	Perf Month	-30.44%
Enterprise Value	19.41M	PEG	-	EPS next Q	-0.09	Inst Own	15.66%	Short Float	3.73%	Perf Quarter	-32.77%
Income	-18.63M	P/S	10.47	EPS this Y	22.34%	Inst Trans	9.74%	Short Ratio	2.84	Perf Half Y	-33.51%
Sales	2.29M	P/B	4.03	EPS next Y	2.74%	ROA	-112.32%	Short Interest	2.03M	Perf YTD	-31.10%
Book/sh	0.10	P/C	2.59	EPS next 5Y	15.36%	ROE	-455.80%	52W High	1.29 -69.22%	Perf Year	-63.24%
Cash/sh	0.15	P/FCF	-	EPS past 3/5Y	21.27% 4.34%	ROIC	-184.83%	52W Low	0.31 29.44%	Perf 3Y	-61.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.88% 17.18%	Gross Margin	24.87%	Volatility	9.98% 10.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	8.48	EPS Y/Y TTM	33.45%	Oper. Margin	-766.95%	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.95	Sales Y/Y TTM	40.77%	Profit Margin	-812.27%	RSI (14)	34.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.53	EPS Q/Q	70.49%	SMA20	-18.12%	Beta	-2.29	Target Price	4.00
Payout	-	Debt/Eq	0.80	Sales Q/Q	39.86%	SMA50	-22.60%	Rel Volume	0.72	Prev Close	0.40
Employees	54	LT Debt/Eq	0.72	Earnings	Mar 31 AMC	SMA200	-39.35%	Avg Volume	717.05K	Price	0.40
IPO	Jun 18, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	124.01% -23.18%	Trades		Volume	517,740	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-25	Initiated	Laidlaw	Buy	$6.50

Apr-01-26 09:00AM	Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth (GlobeNewswire)
Mar-31-26 04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update (GlobeNewswire) +11.76%
Mar-18-26 09:00AM	Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors (GlobeNewswire)
Mar-10-26 09:00AM	Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment (GlobeNewswire)
Feb-27-26 05:26PM	Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
09:00AM	Loading…
Feb-26-26 09:00AM	Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access (GlobeNewswire)
Feb-23-26 09:00AM	Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination (GlobeNewswire)
Feb-03-26 09:15AM	Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products (GlobeNewswire)
Jan-14-26 09:00AM	Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire) +17.81%
Jan-13-26 09:00AM	Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed in Community-Based Care (GlobeNewswire)
Dec-18-25 09:15AM	Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device (GlobeNewswire)
Nov-25-25 09:15AM	PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment (Business Wire) +7.78%
Nov-14-25 04:01PM	Femasys Announces Third Quarter Financial Results for 2025 (GlobeNewswire) +8.58% -11.28%
Nov-10-25 09:00AM	Femasys Advances Global Growth with Second Partner Order for FemBloc in Europe (GlobeNewswire)
Nov-03-25 08:30AM	Femasys Secures FDA Approval to Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million (GlobeNewswire)
09:00AM	Loading…
Oct-22-25 09:00AM	Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc Permanent Birth Control in Europe (GlobeNewswire) -9.57%
Oct-16-25 09:00AM	Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo (GlobeNewswire) +35.38%
Sep-25-25 09:00AM	Femasys Accelerates European Growth for FemBloc with Kebomed Partnership (GlobeNewswire)
Sep-23-25 09:20AM	Femasys partners with Medical Electronic Systems for FemSperm kit (TipRanks)
Sep-22-25 09:00AM	Femasys Partners with Medical Electronic Systems to Launch FemSperm Analysis Kit for use with FemaSeed (GlobeNewswire)
Sep-11-25 09:00AM	Femasys Expands FemSperm Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed (GlobeNewswire)
Sep-08-25 09:00AM	Femasys Secures Regulatory Approval for FemBloc Permanent Birth Control in New Zealand (GlobeNewswire)
Sep-02-25 09:00AM	Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios (GlobeNewswire) +12.62%
Aug-27-25 12:02PM	Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale (Insider Monkey)
Aug-25-25 11:44PM	Femasys Announces Pricing of $8.0 Million Underwritten Public Offering (GlobeNewswire) -9.79% -27.00%
Aug-21-25 09:00AM	Femasys Announces FemSperm Kit to Activate Gynecologists and Advance FemaSeed Fertility Platform (GlobeNewswire) -8.66%
Aug-20-25 09:00AM	Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control (GlobeNewswire) -7.38%
Aug-08-25 05:15PM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -13.16%
04:05PM	Femasys Announces Second Quarter Financial Results for 2025 (GlobeNewswire)
Aug-07-25 09:25AM	Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.33%
06:50PM	Loading…
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion (GlobeNewswire)
Jul-01-25 09:00AM	Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed for First-Line Infertility Treatment and FemVue Diagnostic (GlobeNewswire)
Jun-25-25 09:00AM	Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control (GlobeNewswire) +10.71%
Jun-17-25 09:00AM	Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth (GlobeNewswire)
Jun-11-25 09:00AM	Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations (GlobeNewswire) +6.25%
May-30-25 08:00AM	Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million (GlobeNewswire) -13.73%
May-29-25 04:23PM	Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.83%
05:01PM	Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update (GlobeNewswire)
May-06-25 09:05AM	Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates (Zacks)
Mar-27-25 10:10AM	Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -12.17%
09:00AM	Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update (GlobeNewswire)
Mar-20-25 11:06AM	Femasys price target raised to $15 from $12 at H.C. Wainwright (TipRanks)
Mar-19-25 09:20AM	Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
09:00AM	Femasys Secures Distribution Partnerships for Commercialization of FemBloc in Spain (GlobeNewswire)
Mar-13-25 08:30AM	Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach (GlobeNewswire)
Feb-25-25 09:20AM	Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc Permanent Birth Control Clinical Trials (GlobeNewswire)
Feb-11-25 09:00AM	Femasys Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices (GlobeNewswire) +7.76%
Feb-05-25 07:28AM	Femasys gains approvals for infertility and diagnostic products in Israel (Medical Device Network) +6.19%
Feb-04-25 09:00AM	Femasys Announces Israeli Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices (GlobeNewswire)
Jan-30-25 08:30AM	Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control (GlobeNewswire)
Jan-16-25 08:30AM	Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed for Female Infertility Treatment (GlobeNewswire)
Dec-03-24 09:00AM	Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed (GlobeNewswire)
Nov-26-24 08:30AM	Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment (GlobeNewswire)
Nov-12-24 09:45AM	Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -11.59%
08:30AM	Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update (GlobeNewswire)
Nov-07-24 08:30AM	Femasys to Exhibit at the Annual AAGL 2024 Global Conference (GlobeNewswire)
Nov-01-24 08:30AM	Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control (GlobeNewswire) -5.26%
Oct-30-24 09:00AM	Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed (GlobeNewswire)
Oct-10-24 08:30AM	Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program (GlobeNewswire)
Oct-08-24 08:30AM	Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-02-24 08:30AM	Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed Infertility Treatments (GlobeNewswire)
Sep-18-24 08:30AM	Femasys Announces Infertility Clinic Customers from Coast to Coast (GlobeNewswire)
Sep-11-24 08:30AM	Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed for over $1.3M in Spanish Market (GlobeNewswire) +7.48%
Sep-09-24 11:53AM	FDA clears FemChec for fallopian tube occlusion testing (Medical Device Network)
08:30AM	Femasys Inc. Receives U.S. FDA Clearance to Market FemChec , an Innovative Diagnostic Solution for Fallopian Tube Check (GlobeNewswire)
Sep-05-24 08:30AM	Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting (GlobeNewswire)
Sep-03-24 08:30AM	Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.84%
Aug-30-24 06:32AM	Femasys secures CE mark certification for FemVue MINI solution (Medical Device Network)
Aug-29-24 08:30AM	Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution (GlobeNewswire) +10.48%
Aug-27-24 08:30AM	Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters (GlobeNewswire)
Aug-08-24 09:45AM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -18.09%
08:30AM	Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:30AM	Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam (GlobeNewswire) +10.58%
Jun-21-24 04:32AM	Femasys gains CE Mark approval for womens health products (Medical Device Network) -9.45%
Jun-20-24 08:30AM	Femasys Receives CE Mark Approval for Four of its Women's Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe (GlobeNewswire) +32.98%
May-17-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative (GlobeNewswire)
May-16-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council (GlobeNewswire)
May-09-24 01:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.63%
09:40AM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update (GlobeNewswire)
May-07-24 08:30AM	Femasys Expands Commercial Management Team with Addition of Experienced New Hires (GlobeNewswire) +5.19%
May-02-24 10:01AM	Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-18-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives (GlobeNewswire)
Mar-28-24 10:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.44% +10.97%
04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:00AM	Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape (GlobeNewswire)
Mar-20-24 08:15AM	Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility (GlobeNewswire) -10.00%
Mar-13-24 09:00AM	Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 (GlobeNewswire) -5.24%
Mar-06-24 09:00AM	Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution (GlobeNewswire) -11.27%
Feb-28-24 09:00AM	Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF (GlobeNewswire) +9.26%
Feb-06-24 08:30AM	Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer (GlobeNewswire) +13.27%
Jan-26-24 08:00AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women (GlobeNewswire)
Jan-23-24 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology (GlobeNewswire)
Dec-15-23 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine (GlobeNewswire)
Nov-30-23 08:30AM	Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 05:27PM	30 Countries with the Lowest Median Age in the World (Insider Monkey)

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FEMY

Femasys Inc

Upgrade your Finviz experience